Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-06-23FDA Approved: ONDANSETRON — Supplemental Application (NorthStar Rx LLC)
The FDA approved a supplemental application for ondansetron hydrochloride (generic ondansetron) from NorthStar Rx LLC under ANDA078776. The …
-
FDA approval · 2022-06-23FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for ondansetron hydrochloride from Hikma Pharmaceuticals USA Inc.
-
FDA approval · 2022-06-14FDA Approved: ONDANSETRON — Supplemental Application (AvPAK)
FDA approved a supplemental application for ondansetron from AvPAK.
-
FDA approval · 2022-06-10FDA Approved: ONDANSETRON — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for ondansetron hydrochloride filed by Fresenius Kabi USA, LLC.
-
FDA approval · 2022-06-10FDA Approved: ONDANSETRON — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for ondansetron hydrochloride (ondansetron), a generic product manufactured by Fresenius Kabi USA, L…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-05-25Clinical Trial Update: Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy [Phase 2]
A Phase 2 trial evaluating pantoprazole as a prophylaxis against delayed chemotherapy-induced nausea and vomiting in patients receiving brea…
-
CLINICAL_TRIALS trial_result · 2022-05-20Clinical Trial Update: Capsaicin to Prevent Delayed Chemotherapy Induced Nausea and Vomiting (CapCIN) [Phase 2]
Phase 2 trial update for capsaicin to prevent delayed chemotherapy-induced nausea and vomiting (CapCIN) has completed.
-
FDA approval · 2022-05-19FDA Approved: GRANISETRON — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for granisetron hydrochloride (granisetron) from Fresenius Kabi USA, LLC, expanding its regulatory a…
-
FDA approval · 2022-05-02FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (fosaprepitant dimeglumine) from Merck Sharp & Dohme LLC, updating the drug's regulato…
-
FDA approval · 2022-04-28FDA Approved: CESAMET — Supplemental Application (Bausch Health US LLC)
FDA approved a supplemental application for Cesamet (nabilone) submitted by Bausch Health US LLC.
-
CLINICAL_TRIALS trial_result · 2022-04-20Clinical Trial Update: Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents [Phase 2]
Phase 2 clinical trial update evaluating granisetron transdermal patch for prevention of chemotherapy-induced nausea and vomiting in patient…
-
CLINICAL_TRIALS trial_result · 2022-04-13Clinical Trial Update: Granisetron Transdermal Patch System for Prevention of CINV by CapeOX [Phase 2]
Phase 2 trial update for granisetron transdermal patch to prevent chemotherapy-induced nausea and vomiting with CapeOX regimen.
-
FDA approval · 2022-03-15FDA Approved: ONDANSETRON — Supplemental Application (Hospira, Inc.)
FDA approves Hospira, Inc.'s supplemental application for ondansetron, authorizing changes to the approved product.
-
FDA approval · 2022-03-15FDA Approved: ONDANSETRON — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for ondansetron from Hospira, Inc., updating the product's approval under the ANDA.
-
FDA label_change · 2022-03-14FDA Approved: CINVANTI — Supplemental Application (Heron Therapeutics, Inc.)
FDA approved a supplemental application for CINVANTI (aprepitant) submitted by Heron Therapeutics, Inc. The action involves changes to the p…
-
FDA approval · 2022-03-11FDA Approved: ONDANSETRON — Supplemental Application (JVET PHARMACEUTICALS LLC)
The FDA approved a supplemental application for ondansetron from JVET PHARMACEUTICALS LLC, enabling this generic product's expanded approval…
-
FDA approval · 2022-03-11FDA Approved: ONDANSETRON — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for a generic ondansetron product from Heritage Pharmaceuticals (Avet) under the ANDA process.
-
FDA approval · 2022-03-01FDA Approved: ONDANSETRON — Supplemental Application (Eugia US LLC)
The FDA approved a supplemental application for a generic ondansetron hydrochloride product from Eugia US LLC under ANDA 202600. This approv…
-
FDA label_change · 2022-02-28FDA Approved: ONDANSETRON — Supplemental Application (Qilu Pharmaceutical Co., Ltd.)
FDA approved a supplemental application for ondansetron from Qilu Pharmaceutical Co., Ltd., likely resulting in labeling changes for this ge…
-
CLINICAL_TRIALS trial_result · 2022-02-23Clinical Trial Update: Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer [Phase 2]
Phase 2 trial evaluating olanzapine, netupitant, and palonosetron for controlling nausea and vomiting induced by highly emetogenic chemother…
-
CLINICAL_TRIALS trial_result · 2022-01-21Clinical Trial Update: Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis [Phase 3]
Phase 3 trial update evaluating olanzapine for chemotherapy-induced nausea and vomiting prophylaxis has completed.
-
CLINICAL_TRIALS trial_result · 2021-12-14Clinical Trial Update: Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin [Phase 2, Phase 3]
Phase 2/3 trial update evaluating safety and antiemetic efficacy of Akynzeo with dexamethasone during radiotherapy plus weekly cisplatin in …
-
FDA approval · 2021-11-12FDA Approved: PALONOSETRON HYDROCHLORIDE — Original Application (Baxter Healthcare Corporation)
FDA approved palonosetron hydrochloride from Baxter Healthcare Corporation under an original application. The drug is indicated to prevent c…
-
FDA approval · 2021-10-01FDA Approved: ONDANSETRON — Supplemental Application (AvPAK)
The FDA approved a supplemental application for ondansetron submitted by AvPAK.
-
FDA approval · 2021-10-01FDA Approved: ONDANSETRON — Supplemental Application (Accord Healthcare, Inc.)
FDA approved Accord Healthcare, Inc.'s supplemental application for ondansetron, indicating an approved change to the product's labeling.